Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innoviva (INVA) Convertible Debt (2010 - 2017)

Innoviva posted quarterly Convertible Debt of $237.9 million for Q2 2017, down 1.47% year-on-year from $241.4 million in Q2 2016, and little changed on a QoQ basis from $237.7 million in Q1 2017.

Innoviva (INVA) has 8 years of Convertible Debt data on file, last reported at $237.9 million in Q2 2017.

  • For the quarter ending Q2 2017, Convertible Debt fell 1.47% year-over-year to $237.9 million; the trailing twelve-month figure through Jun 2017 stood at $237.9 million (down 1.47% YoY), and the FY2016 full-year result was $237.6 million, down 5.34% from the prior year.
  • Convertible Debt for Q2 2017 stood at $237.9 million, roughly flat from $237.7 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $460.0 million in Q1 2013 and bottomed at $237.6 million in Q4 2016.
  • The 5-year median for Convertible Debt is $255.1 million (2014), against an average of $280.2 million.
  • The widest annual swing landed in 2013, when Convertible Debt surged 166.67%; it then sank 37.5% in 2014.
  • A 5-year view of Convertible Debt shows it stood at $287.5 million in 2013, then slipped by 11.27% to $255.1 million in 2014, then fell by 1.61% to $251.0 million in 2015, then decreased by 5.34% to $237.6 million in 2016, then gained by 0.11% to $237.9 million in 2017.
  • The last three Convertible Debt figures came in at $237.9 million (Q2 2017), $237.7 million (Q1 2017), and $237.6 million (Q4 2016), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Innoviva 1.60 Bn 992.84 Mn 75.83 Mn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2017 237.86 Mn
Mar 31, 2017 237.72 Mn
Dec 31, 2016 237.60 Mn
Sep 30, 2016 241.54 Mn
Jun 30, 2016 241.41 Mn
Mar 31, 2016 251.12 Mn
Dec 31, 2015 250.99 Mn
Sep 30, 2015 255.11 Mn
Jun 30, 2015 255.11 Mn
Mar 31, 2015 255.11 Mn
Dec 31, 2014 255.11 Mn
Sep 30, 2014 255.11 Mn
Jun 30, 2014 287.50 Mn
Mar 31, 2014 287.50 Mn
Dec 31, 2013 287.50 Mn
Sep 30, 2013 287.50 Mn
Jun 30, 2013 459.96 Mn
Mar 31, 2013 460.00 Mn
Dec 31, 2012 172.50 Mn
Sep 30, 2012 172.50 Mn
Jun 30, 2012 172.50 Mn
Mar 31, 2012 172.50 Mn
Dec 31, 2011 172.50 Mn
Sep 30, 2011 172.50 Mn
Jun 30, 2011 172.50 Mn
Dec 31, 2010 172.50 Mn